Recombinant Protein G, His Tag is fused with the polyhistidine tag at N-terminus and a single cysteine at C-terminus. The reducing (R) protein migrates as a 29 kDa polypeptide. Protein G Protein can bind to human IgG1 Fc.
>98% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 100 mM NaH2PO4, pH8.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Recombinant Protein G, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 98%.
Authors: Sun Y, Li Z, Liang W, et al.
Journal: Scientific reports vol 2020
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $85.00
Price(USD) : $170.00
Price(USD) : $2500.00
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.